GKOS

Glaukos Corp

GKOS, USA

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

https://www.glaukos.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GKOS
stock
GKOS

Glaukos (NYSE:GKOS) CEO Sells $10,126,325.00 in Stock MarketBeat

Read more →
GKOS
stock
GKOS

Burns, Glaukos chairman & ceo, sells $31.6 million in GKOS stock By Investing.com Investing.com South Africa

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$126.2143

Analyst Picks

Strong Buy

9

Buy

3

Hold

2

Sell

0

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

8.51

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-2.11 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-1.62 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-8.78 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.30

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 107.76% of the total shares of Glaukos Corp

1.

BlackRock Inc

(15.2127%)

since

2025/06/30

2.

FMR Inc

(11.049%)

since

2025/06/30

3.

Vanguard Group Inc

(10.6578%)

since

2025/06/30

4.

iShares Core S&P Small-Cap ETF

(5.9248%)

since

2025/08/31

5.

Wellington Management Company LLP

(5.6572%)

since

2025/06/30

6.

State Street Corp

(3.6449%)

since

2025/06/30

7.

Ameriprise Financial Inc

(3.4861%)

since

2025/06/30

8.

PRIMECAP Management Company

(3.1874%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(2.9985%)

since

2025/07/31

10.

iShares Russell 2000 ETF

(2.3479%)

since

2025/08/31

11.

Geode Capital Management, LLC

(2.3201%)

since

2025/06/30

12.

Vanguard Small Cap Index

(2.2979%)

since

2025/07/31

13.

AllianceBernstein L.P.

(2.1828%)

since

2025/06/30

14.

Westfield Capital Management Company, L.P.

(2.0364%)

since

2025/06/30

15.

Brown Capital Management, LLC

(1.9863%)

since

2025/06/30

16.

William Blair Investment Management, LLC

(1.981%)

since

2025/06/30

17.

American Funds SMALLCAP World A

(1.9136%)

since

2025/06/30

18.

HHG PLC

(1.8957%)

since

2025/06/30

19.

Holocene Advisors, LP

(1.8237%)

since

2025/06/30

20.

Vanguard Health Care Inv

(1.7832%)

since

2025/06/30

21.

Amvescap Plc.

(1.7386%)

since

2025/06/30

22.

PRIMECAP Odyssey Aggressive Growth

(1.6388%)

since

2025/06/30

23.

Capital World Investors

(1.4837%)

since

2025/06/30

24.

Vanguard Explorer Inv

(1.4141%)

since

2025/06/30

25.

Vanguard Small Cap Growth Index Inv

(1.2948%)

since

2025/07/31

26.

NORGES BANK

(1.2883%)

since

2025/06/30

27.

Point72 Asset Management, L.P.

(1.2542%)

since

2025/06/30

28.

Gilder Gagnon Howe & CO LLC

(1.2217%)

since

2025/06/30

29.

Charles Schwab Investment Management Inc

(1.2214%)

since

2025/06/30

30.

Vanguard Capital Opportunity Inv

(1.2214%)

since

2025/06/30

31.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0709%)

since

2025/07/31

32.

Janus Henderson US SMID Cap Growth

(1.0587%)

since

2025/06/30

33.

Janus Henderson US SMID Cap Growth MA

(1.0587%)

since

2025/06/30

34.

Janus Henderson Triton D

(1.0587%)

since

2025/06/30

35.

Fidelity Small Cap Index

(0.9782%)

since

2025/06/30

36.

Columbia Small Cap Growth Inst

(0.8883%)

since

2025/07/31

37.

Columbia Small Cap Growth

(0.8883%)

since

2025/06/30

39.

iShares S&P Small-Cap 600 Growth ETF

(0.8573%)

since

2025/08/31

40.

iShares Russell 2000 Growth ETF

(0.8565%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.16

EPS Estimate

-0.2586

EPS Difference

0.0986

Surprise Percent

38.1284%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(1.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.